FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken (Reuters) - AstraZeneca Plc <AZN.L> said on Friday it would sell commercial rights for ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal ...

Cheplapharm will pay AstraZeneca a total of $400m in non-contingent consideration, of which the present value will be recognised as Other Operating Income upon completion of the transaction, ...

AstraZeneca (NASDAQ:AZN), Sanofi (NASDAQ:SNY) and Swedish Orphan Biovitrum (Sobi) (OTCPK:BIOVF) updated their contracts related to developing and commercializing respiratory syncytial virus (RSV) ...

As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost its American manufacturing and R&D infrastructure. Chief among the company’s ...

The FDA has concluded that Andexxa's risk profile is no longer favorable. AstraZeneca will stop sales of Andexxa in US.

Pharma companies are seeing the value of digital health, and are creating departments focused on developing, scaling and investing in platforms that use technology to enhance life sciences R&D, better ...

(RTTNews) - AstraZeneca plc (AZN.L, AZN) has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm.

FRANKFURT, Nov 18 (Reuters) - AstraZeneca (AZN.L), opens new tab said its antibody cocktail against COVID-19 would - unlike its vaccine - be priced commercially as it negotiates supply contracts with ...

(Reuters) - AstraZeneca Plc said on Friday it would sell commercial rights for two of its drugs to a German pharmaceutical company for $400 million as the British drugmaker looks to focus on newer ...